Current guidelines for many critical illnesses recommend targeting a MAP of 65 mm Hg, with consideration of higher MAPs in older patients with chronic HTN. Recent literature, however, suggests increased mortality in older patients who are exposed to larger quantities of vasopressor medications. In this podcast, we do a deep dive into the recently published 65 Trial, which sought to evaluate the effect of permissive hypotension in older patients with vasodilatory hypotension.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
Approximately 350,000 adults in the US experience an out-of-hospital cardiac arrest (OHCA). Despite numerous potential improvements in treatments, survival from OHCA remains essentially unchanged...
This month Mike McCurdy rejoins the podcast to discuss the ATHOS-3 trial. Mike was one of the co-authors on this impressive publication and gives...
Traumatic hemothorax has traditionally been treated with a large bore thoracostomy to prevent retained hemothorax and morbidity. In this podcast we discuss the results...
